Evidence map›Paper›PMID 38416822›Full record

ArticleScience advances2024

Stat5 induces androgen receptor (

Cristina Maranto, Lavannya Sabharwal, Vindhya Udhane, Samuel P Pitzen, Braedan McCluskey, Songyan Qi, Christine O'Connor, Savita Devi, Scott Johnson, Kenneth Jacobsohn and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Targeting the JAK/STAT signalling axis in cancer: chemopreventive potential of natural compounds with emerging focus on retinoids.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Cristina MarantoDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-9437-1958
Lavannya SabharwalDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0001-6022-029X
Vindhya UdhaneDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Samuel P PitzenMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6556-0461
Braedan McCluskeyMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0001-6423-7048
Songyan QiMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0009-0009-6157-006X
Christine O'ConnorMinnesota Supercomputing Institute, University of Minnesota, Minneapolis, MN 55455, USA.
Savita DeviDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Scott JohnsonDepartment of Urology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-2946-0601
Kenneth JacobsohnDepartment of Urology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0003-2039-2737
Anjishnu BanerjeeInstitute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0000-0002-6898-9148
Kenneth A IczkowskiDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
Liang WangDepartment of Tumor Biology, Moffitt Cancer Center, 12902 USF Magnolia Drive, Tampa, FL 33612, USA.ORCID 0000-0002-9364-8572
Scott M DehmMasonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.ORCID 0000-0002-7827-5579
Marja T NevalainenDepartment of Pathology, Medical College of Wisconsin, Milwaukee, WI 53226, USA.ORCID 0009-0008-8593-078X
Medical College of Wisconsin · USUniversity of Minnesota · USMoffitt Cancer Center · US

Funding

Cell free nucleic acid-based biomarkers in advanced prostate cancerR01CA212097 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI KOHLI, MANISH, WANG, LIANG · 2017 to 2022
$3.1M
Pharmacological Jak2 inhibition to overcome androgen receptor aberrations in prostate cancerR01CA262570 · NCI · THOMAS JEFFERSON UNIVERSITY · PI Scott M. Dehm, MARJA T NEVALAINEN · 2022 to 2026
$2.9M
NCI NIH HHS R01 CA212097NCI NIH HHS R01 CA262570
6 · The paper itself

Abstract

Androgen receptor (AR) drives prostate cancer (PC) growth and progression, and targeting AR signaling is the mainstay of pharmacological therapies for PC. Resistance develops relatively fast as a result of refueled AR activity. A major gap in the field is the lack of understanding of targetable mechanisms that induce persistent AR expression in castrate-resistant PC (CRPC). This study uncovers an unexpected function of active Stat5 signaling, a known promoter of PC growth and clinical progression, as a potent inducer of

Indexed as

Prostatic Neoplasms, Castration-ResistantReceptors, AndrogenCell Line, TumorGene Expression Regulation, NeoplasticHumansMaleSignal TransductionTranscription, GeneticReceptors, Androgen

Identifiers

PMID38416822
PMCPMC10901378
OpenAlexW4392265986

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.